^
    2d
    Testing the SurVaxM Vaccine for Lung Cancer Prevention (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2027 --> Sep 2029 | Initiation date: Feb 2026 --> Jun 2026 | Trial primary completion date: Sep 2027 --> Mar 2029
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    SurVaxM (SVN53-67/M57-KLH peptide vaccine) • Leukine (sargramostim)
    13d
    MRI of combination immunotherapy in an epithelial ovarian cancer preclinical model. (PubMed, Npj Imaging)
    We studied MRI immune cell tracking in a murine model of ovarian cancer using a clinically relevant treatment combination of DPX-Survivac, anti-PD-1, and an intermittent low dose of Cyclophosphamide (CPA). The density of SPIO-labeled myeloid and CD8+ T cells in tumors was higher in the treatment group than in the control group. This study provides insights into how MRI can be used in concert with biological assays to study how immunotherapy and chemotherapy combinations exert their antitumor effects.
    Preclinical • Journal
    |
    CD8 (cluster of differentiation 8)
    |
    cyclophosphamide • maveropepimut-S (MVP-S)
    20d
    Dual-targeted approaches in cancer therapy: integrating siRNA and chemotherapy for improved outcomes. (PubMed, 3 Biotech)
    Early clinical candidates, such as EZN-3042 and ALN-VSP, achieved target engagement and biological activity, while limitations included variable tumour uptake, dose-limiting toxicities, and complex pharmacokinetic behaviour. Translation to clinical practice will depend on optimised delivery platforms, reproducible pharmacokinetic/pharmacodynamic synchronisation, and rigorous evaluation of safety and off-target effects. Overall, current evidence highlights substantial potential for siRNA-drug co-delivery while emphasizing key challenges to overcome in achieving durable clinically meaningful outcomes.
    Review • Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • MET (MET proto-oncogene, receptor tyrosine kinase) • BCL2 (B-cell CLL/lymphoma 2) • MUC1 (Mucin 1) • BIRC5 (Baculoviral IAP repeat containing 5)
    23d
    NCI-2015-00694: SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov)
    P2, N=66, Active, not recruiting, Roswell Park Cancer Institute | Trial completion date: Mar 2026 --> Jun 2026
    Trial completion date
    |
    temozolomide • SurVaxM (SVN53-67/M57-KLH peptide vaccine) • Leukine (sargramostim)
    1m
    Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas (clinicaltrials.gov)
    P2, N=60, Recruiting, Roswell Park Cancer Institute | Suspended --> Recruiting
    Enrollment open
    |
    temozolomide • SurVaxM (SVN53-67/M57-KLH peptide vaccine) • Leukine (sargramostim)
    2ms
    NCI-2015-00694: SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov)
    P2, N=66, Active, not recruiting, Roswell Park Cancer Institute | Trial completion date: Nov 2025 --> Mar 2026
    Trial completion date
    |
    temozolomide • SurVaxM (SVN53-67/M57-KLH peptide vaccine) • Leukine (sargramostim)
    3ms
    Triplet RNA Lipid Nanoparticles for Locoregional Cancer Immunotherapy. (PubMed, Small Sci)
    This study demonstrates the potential of a triplet RNA platform-comprising immunostimulatory RNA, mRNA, and siRNA, delivered via a single versatile LNP. The data support development of pIpC-LNPs as potent intratumoral therapeutics and highlight several potential synergistic targets.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD70 (CD70 Molecule) • CD27 (CD27 Molecule) • TNFSF4 (TNF Superfamily Member 4)
    3ms
    Itaconate-Related Gene Signatures as Prognostic Markers in Colon Cancer: Insights From Transcriptomic and Spatial Analysis. (PubMed, Hum Mutat)
    Drug sensitivity analysis identified four potentially effective drugs, such as sepantronium bromide, which had better effects on high-risk patients. This study provides a theoretical basis and new targets for precise prognosis and stratified treatment of colon cancer.
    Journal • Tumor mutational burden • Gene Signature • IO biomarker
    |
    TMB (Tumor Mutational Burden) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CD36 (thrombospondin receptor) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • CXCL1 (Chemokine (C-X-C motif) ligand 1)
    |
    sepantronium bromide (PC-002)
    4ms
    Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas (clinicaltrials.gov)
    P2, N=60, Suspended, Roswell Park Cancer Institute | Not yet recruiting --> Suspended
    Trial suspension
    |
    temozolomide • SurVaxM (SVN53-67/M57-KLH peptide vaccine) • Leukine (sargramostim)
    4ms
    From bioinformatics to clinical translation: BIRC5 as a pivotal diagnostic biomarker and therapeutic target for NAFLD-driven HCC. (PubMed, Cell Biol Toxicol)
    This study proposes BIRC5 as a therapeutic target and diagnostic biomarker, offering perspectives for HCC diagnosis and treatment of HCC. These results underscore the importance of BIRC5 in halting NAFLD-HCC progression and provide valuable insights for future clinical applications.
    Journal
    |
    TOP2A (DNA topoisomerase 2-alpha) • BIRC5 (Baculoviral IAP repeat containing 5) • CDK1 (Cyclin-dependent kinase 1) • CCNB1 (Cyclin B1)
    |
    sepantronium bromide (PC-002)